A new look at evaluating MTD designs in cancer research

DOI10.1080/15598608.2009.10411930MaRDI QIDQ2431683zbMATH OpenOpenAlexFDO

Authors L. T. Tremmel

Publication date 18 April 2011

Published in Journal of Statistical Theory and Practice (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1080/15598608.2009.10411930

zbMATH Keywords

maximum tolerated dosetolerance distributionprobit regressiondose escalation designs

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50) Nonparametric inference (62G99)

Recommendations

• Design and Analysis of Phase I Clinical Trials
• The treatment versus experimentation dilemma in dose finding studies
• Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
• An assessment of up- and down designs and associated estimators in phase I trials
• A method based on isotonic regression estimation for identifying the maximum tolerated dose

Cites work

• A Random Walk Rule for Phase I Clinical Trials
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Design and Analysis of Phase I Clinical Trials

Cited in

(10)

• A method based on isotonic regression estimation for identifying the maximum tolerated dose
• Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose
• An assessment of up- and down designs and associated estimators in phase I trials
• Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
• Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
• Adaptive clinical trial designs for phase I cancer studies
• The treatment versus experimentation dilemma in dose finding studies
• The role of minimal sets in dose finding studies
• Design and Analysis of Phase I Clinical Trials
• Sequential designs for dose escalation studies in oncology

This page was built for publication: A new look at evaluating MTD designs in cancer research

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2431683)